Oncology - Pharma Deals News, page-89

Just did a quick conversion to extrapolate what these companies were valued at when the deals were made, and I must admit I have no idea how these companies compare/relate to RAC (but I have a fair idea wombat does and this is why he listed them), but the deal values are between ~0.6 and $20 Billion. Even the smallest one is 2.5x RAC's current MC, and of course the deal itself then still sets the scene for a massive further growth (even if it's for 50% of the gain only).

		%	$M	Equiv $M for 100%
1	Forty Seven	100%	4,900	4,900
2	Arcus	13%	375	2,885
3	Pionyr	50%	275	550
4	Tizona	50%	300	600
5	Tango	7%	145	2,071
6	Jounce	14%	120	857
7	Immunomedics	100%	21,000	21,000